Latest Neuropathic pain Stories

Chief Scientist Will Also Be Presenting at 4th International Congress on Neuropathic Pain in Toronto LONDON, May 20, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, will be giving two presentations today at...

Peripheral Neuropathy affects an estimated 24 million people in America alone. For people suffering from Peripheral Neuropathy, Neuracel has come up with a product that combines the best natural ingredients to provide pain relief at http://www.neuracel.com. Boise, Idaho (PRWEB) May 17, 2013 According to the latest research conducted by the Back and Pain Relief Center in April, 2013, an estimated 24 million Americans suffer from Peripheral Neuropathy. The condition is more likely to affect...

Increase in Diabetic Neuropathy Escalates Neuropathy Epidemic Impacting Millions According to The Neuropathy Association. New York, NY (PRWEB) May 13, 2013 According to The Neuropathy Association, there are now 15-18 million Americans with diabetic peripheral neuropathy (DPN) due to the increasing prevalence of diabetes. 60-70% of the 25.8 million adults and children in the U.S. with diabetes have DPN.* The growing DPN statistic significantly raises the overall number of people with...

CAMBRIDGE, England, April 23, 2013 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd. The trial is a randomised...

Returning veterans with major limb injuries Veterans who sustained major limb injuries during combat reported little improvement in symptoms of depression, anxiety, post-traumatic stress disorder (PTSD) and other mental-health problems up to 2 years post injury, according to research presented today. In contrast, pain showed the most improvement 3-6 months after acute hospitalization, and then leveled off after 1 year. The investigative team, led by Rollin M. Gallagher, MD, MPH, reported...

University of North Carolina Health Care A study from the University of North Carolina School of Medicine offers new insights into how the nervous system processes hot and cold temperatures. The research led by neuroscientist Mark J. Zylka, PhD, associate professor of cell biology and physiology, found an interaction between the neural circuits that detect hot and cold stimuli: cold perception is enhanced when nerve circuitry for heat is inactivated. "This discovery has implications for...

Study Highlights: -Chronic or persistent pain is a common complication of clot-caused strokes. -Pain may occur even when a stroke is of mild or moderate severity, and may not begin until months later. -Stroke patients who develop chronic pain are more likely to have physical and cognitive decline. Chronic or persistent pain is a common — and likely under-recognized — complication of ischemic strokes (caused by a blocked blood vessel) according to new research in the American Heart...

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA. "Approximately 20 percent to 40 percent of patients with cancer who receive neurotoxic chemotherapy (e.g., taxanes, platinums, vinca alkaloids, bortezomib) will develop painful chemotherapy-induced peripheral neuropathy. Painful chemotherapy-induced...

CAMBRIDGE, England, March 27, 2013 /PRNewswire/ -- Novel sodium channel blocker with excellent pharmacokinetic and safety profile could fill treatment gap for severe pain condition Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel analgesic medicines for the treatment of chronic pain, today announces positive interim data from the ongoing Phase II clinical trial of novel sodium channel blocker...

MELBOURNE, Australia, March 27, 2013 /PRNewswire/ -- Spinifex Pharmaceuticals, an Australian pain drug development company, today announces it has received an approximately AUS$1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain. The R&D Incentive Program is an annual scheme, jointly administered by AusIndustry and the Australian Taxation Office, which enables Spinifex to...